Updated Jul 16, 2026 · Last SEC filing 2026-07-02
Royalty Pharma plc (RPRX) has filed 22 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-02. 3 Form 8-K material event filings were reported by RPRX in the last 90 days. 10 Form 144 notices of proposed sale were filed for RPRX stock. InsiderAlpha tracks every RPRX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001802768 |
|---|
| Form 4 filings (90d) | 22 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 10 |
| Latest Form 4 filing | 2026-07-02 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Urist Marshall | EVP, Research & Investments | S — Open-market sale | 9.1K | $55.88 | $508K | SEC | |
| Hite Christopher | EVP & Chairman, Partnering | S — Open-market sale | 2.6K | $57.10 | $146K | SEC | |
| Bassler Bonnie L | Director | A — Grant or award | 689 | $54.40 | $37K | SEC | |
| Hite Christopher | EVP & Chairman, Partnering | S — Open-market sale | 29.4K | $56.44 | $1.66M | SEC | |
| Hite Christopher | EVP & Chairman, Partnering | S — Open-market sale | 600 | $57.09 | $34K | SEC | |
| Hite Christopher | EVP & Chairman, Partnering | S — Open-market sale | 97.4K | $56.50 | $5.51M | SEC | |
| Urist Marshall | EVP, Research & Investments | S — Open-market sale | 9.1K | $55.18 | $502K | SEC | |
| Hite Christopher | EVP & Chairman, Partnering | S — Open-market sale | 32.4K | $54.11 | $1.75M | SEC | |
| Hite Christopher | EVP & Chairman, Partnering | S — Open-market sale | 117.6K | $54.47 | $6.41M | SEC | |
| Engelbert Catherine M. | Director | A — Grant or award | 4.5K | $0.00 | — | SEC | |
| Bassler Bonnie L | Director | A — Grant or award | 4.5K | $0.00 | — | SEC | |
| Coric Vlad | Director | A — Grant or award | 4.5K | $0.00 | — | SEC | |
| WEATHERMAN ELIZABETH H | Director | A — Grant or award | 4.5K | $0.00 | — | SEC | |
| Ho Carole | Director | A — Grant or award | 4.5K | $0.00 | — | SEC | |
| LOVE TED W | Director | A — Grant or award | 4.5K | $0.00 | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Royalty Pharma plc (RPRX). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Hite Christopher | 7 | $15.50M |
| Urist Marshall | 5 | $2.46M |
| Coyne Terrance P. | 4 | $5.21M |
| Norden Gregory | 2 | $161K |
| Bassler Bonnie L | 2 | $37K |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in RPRX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live RPRX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.